Jump to content

Natco Pharma

From Wikipedia, the free encyclopedia

Natco Pharma
Company typePublic
NSE: NATCOPHARM
BSE: 524816
IndustryPharmaceuticals
Founded1981
FounderVC Nannapaneni
Headquarters
Hyderabad, Telangana
,
India
Area served
Global
Key people
VC Nannapaneni (Chairman and MD)[1]
Rajeev Nannapaneni (CEO and Vice Chairman)[2]
RevenueIncrease ₹4,127 crore (US$490 million) (FY24)[3]
Increase ₹1,388 crore (US$170 million) (FY24)[3]
Websitenatcopharma.co.in

Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad. The company manufactures finished dosage formulations active pharmaceutical ingredients and Agro chemical products.[4] It is a major producer of branded oncology medicines[5] cardiology, diabetology and other pharma specialty drugs.[6] The company specialises in producing complex medicines at affordable prices.[7][8] NATCO is a science driven company and focuses on limited competition molecules in the US. [9][10]

History[edit]

  • In 2008, NATCO Pharma filed its first paragraph IV filing in the US with the USFDA, [11]
  • In 2012, NATCO Pharma obtained compulsory license to produce a cheaper and generic version of Bayer's anti-cancer medication Nexavar.[6]
  • In the United States, it launched influenza medication Tamiflu with marketing partner Alvogen, multiple sclerosis treatment drug glatiramer acetate in partnership with Mylan, and hepatitis C drugs under a licensing agreement with Gilead Sciences.[11]
  • In 2016, NATCO Pharma launched the first Tamiflu capsule in the US market.[12]
  • In 2017, NATCO Pharma launched a generic version of blood cancer drug Pomalidomide in the United States.[13]
  • In 2019, NATCO Pharma initiated work on green-field manufacturing facilities for producing niche agrichemical products in Nellore district, Andhra Pradesh.[14]
  • In 2022 Crop Health Sciences division launched Chlorantraniliprole (CTPR) based products.
  • NATCO launched the first generic version of Revlimid in the US market
  • For the financial Year 2024, NATCO recorded its highest ever revenue, Earnings Before Interests Tax Depreciation and Amortization and profit after tax.

External links[edit]

References[edit]

  1. ^ "Facing headwinds in US, Natco Pharma looks to scale up business in China". Livemint. Retrieved 19 April 2020.
  2. ^ "Natco Pharma: In fine fettle". Forbes India. Retrieved 19 April 2020.
  3. ^ a b "Natco Pharma posts 345% sequential growth in Q4 PAT to ₹276 crore". Mint. 29 May 2023. Retrieved 27 June 2023.
  4. ^ "Our Business | Natco Pharma". Retrieved 25 April 2022.
  5. ^ "Natco Pharma lines up 20 'Para IV' products". The Hindu Business Line. Retrieved 19 April 2020.
  6. ^ a b "How Natco defied the odds to rise up India's pharma ladder". Moneycontrol. Retrieved 19 April 2020.
  7. ^ PTI (17 December 2020). "Natco Pharma launches anti blood clot medication, Rivaroxaban, in India". The Economic Times. Retrieved 25 April 2022.
  8. ^ Akolkar, Shrikant (9 March 2017). "Natco Pharma: Top league player" (PDF). Angel One. Retrieved 25 April 2022.
  9. ^ "Mission & Heritage | Natco Pharma". Retrieved 25 April 2022.
  10. ^ Sridhar, G. Naga (25 November 2020). "Natco Pharma expects agri business to be key growth lever". www.thehindubusinessline.com. Retrieved 24 April 2022.
  11. ^ a b "Niche Play". Business Today. Retrieved 19 April 2020.
  12. ^ "Bayer cancer drug faces new Nexavar patent problems in India". www.thepharmaletter.com. Retrieved 3 February 2022.
  13. ^ "Natco Pharma launches blood cancer drug priced Rs 5,000–20,000, down 98% from US price". Firstpost. 10 May 2017. Retrieved 31 July 2020.
  14. ^ "Natco Pharma to invest Rs 100 cr for setting up agrichemical facilities in Andhra". 25 January 2019.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Natco_Pharma&oldid=1231233357"